Promoter Hypermethylation of RASSF1A in Esophageal Squamous Cell Carcinoma

Tamotsu Kuroki, Francesco Trapasso, Sai Yendamuri, Ayumi Matsuyama, Hansjuerg Alder, Masaki Mori, and Carlo M. Croce

Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, Pennsylvania 19107 [T. K., F. T., S. Y., A. M., H. A., C. M. C.], and Department of Surgery, Medical Institute of Bioregulation, Kyushu University, Beppu 874-0838, Japan [M. M.]

ABSTRACT

Purpose: The RAS association domain family 1A (RASSF1A) gene, a candidate tumor suppressor gene, is frequently inactivated by hypermethylation of its promoter region in several human cancers. The aim of this study was to evaluate the promoter methylation status of the RASSF1A in esophageal squamous cell carcinoma.

Experimental Design: We analyzed the methylation status of RASSF1A promoter by methylation-specific PCR in 23 esophageal squamous cell carcinoma cell lines and 48 primary tumors.

Results: Hypermethylation of RASSF1A was found in 74% of cell lines and 52% of primary tumors. The presence of hypermethylation was statistically associated with loss of RASSF1A mRNA expression in both cell lines (P = 0.007) and primary tumors (P = 0.003). There was a statistically significant correlation between the presence of hypermethylation and tumor stage (P = 0.009).

Conclusions: Our findings suggest that epigenetic silencing of RASSF1A gene expression by promoter hypermethylation could play an important role in primary esophageal squamous cell carcinogenesis.

INTRODUCTION

The genesis of human cancers, including those of the esophagus, is a multistep process involving cumulative genetic alterations that include activation of oncoproteins or inactivation of tumor suppressor genes. Although multiple genetic and epigenetic changes have been detected in esophageal squamous cell carcinoma (1–3), the precise molecular mechanisms of development and/or progression of esophageal squamous cell carcinoma still remain unknown.

Examples of genetic alterations involving homozygous deletions and LOH1 of chromosome 3p have been reported in many different human tumors, including esophageal cancer (4, 5). The fragile histidine triad gene, located at 3p14.2, is a tumor suppressor gene that is predominantly altered by deletions, and it plays an important role in the development of esophageal cancers with exposure to environmental carcinogens (1, 6, 7). LOH analyses revealed that 3p21.3 is another region commonly deleted in several cancers (8, 9). Furthermore, we recently reported abnormalities in the WWOX gene, a putative tumor suppressor gene, involving LOH and point mutation (3). Recently, RASSF1A has been proposed as a candidate tumor suppressor gene, isolated within the minimal homozygous deletion at 3p21.3 in lung cancer (10). Recent studies have shown that the hypermethylation of CpG island into regulatory sequences is another mechanism that could account for silencing genes involved in cancer (11–13). The most recurrent mechanism of inactivation of RASSF1A is the hypermethylation of a CpG island in its promoter sequences as reported in lung, breast, prostate, and kidney cancers (14–16). To investigate whether the promoter hypermethylation of RASSF1A could play a role in human esophageal tumorigenesis, we performed a MSP on esophageal primary tumors and cell lines. We investigated the frequency and potential clinical implications of hypermethylation of RASSF1A promoter in human esophageal squamous cell carcinomas.

MATERIALS AND METHODS

Cell Lines and Tissues. Twenty-three human esophageal carcinoma cell lines and 13 TE series were provided by the Cell Resource Center for Biomedical Research Institute of Development, Aging and Cancer at Tohoku University (Tohoku, Japan), and 10 KYSE series were gifts from Dr. Shimada of Kyoto University (Kyoto, Japan). The tumor samples and their corresponding noncancerous tissues were obtained from 48 Japanese patients who underwent surgery for esophageal squamous cell carcinoma (45 male and 3 female; median age, 60.7 years; range, 48–74 years). Four of them were stage I, 5 were stage II, 37 were stage III, and 2 were stage IV, according to the Tumor-Node-Metastasis classification.

DNA and RNA Extraction. The tissue samples were excised and immediately stored at −80°C. DNA and RNA were

1 The abbreviations used are: LOH, loss of heterozygosity; RASSF1A, RAS association domain family 1A; MSP, methylation-specific PCR; RT-PCR, reverse transcription-PCR; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
Hypermethylation of RASSF1A in Esophageal Cancer

locations of primers used for RT-PCR analyses were used for cDNA normalization. The reverse transcription was performed as described previously (1). GAPDH amplification was used for cDNA normalization. The mRNA expression of RASSF1A was analyzed in 23 cell lines and 48 paired esophageal tissues, according to methods described previously (17).

RESULTS

Hypermethylation Analysis of Esophageal Carcinoma Cell Lines. To evaluate the methylation status of the promoter region of RASSF1A in esophageal cancers, we used an MSP approach. Seventeen of 23 (74%) esophageal cancer cell lines showed methylated bands of RASSF1A, and 9 (39%) cell lines showed unmethylated bands. Both methylated and unmethylated bands were detected in 3 (13%) cell lines. The frequency of the methylated and unmethylated RASSF1A alleles is summarized in Table 1. Representative MSP results of cell lines are shown in Fig. 1A.

The mRNA expression of RASSF1A was analyzed in 23 esophageal carcinoma cell lines by RT-PCR. Only 5 of 23 cell lines (TE 1, TE 3, TE 11, TE 14, and KYSE 140) still expressed the RASSF1A mRNA. RT-PCR amplification of RASSF1A in these 5 cell lines revealed a shorter transcript; sequencing analysis of the shorter transcript showed a RASSF1F transcript with a deleted exon 1C of RASSF1A as described previously (14). Representative RT-PCR results of cell lines are shown in Fig. 1B. In 4 of 5 cell lines (TE1, TE11, TE14, and KYSE140), RASSF1A was expressed in the absence of methylated RASSF1A allele. In 1 cell line (TE 3), RASSF1A was expressed in the presence of both methylated and unmethylated RASSF1A alleles. In 2 cell lines (TE 9 and TE 15), RASSF1A was not expressed in the absence of methylated allele (Table 1). There was a significant correlation between RASSF1A promoter hypermethylation and RASSF1A expression in cell lines ($P = 0.007$; Fisher’s exact test).

Hypermethylation Analysis of Primary Esophageal Squamous Cell Carcinomas. Hypermethylation of the promoter region of RASSF1A was detected in 25 of 48 (52%) esophageal cancers. Unmethylated bands were detected in 37 of 48 (77%) tumor samples. In primary tumors, the presence of the remaining stromal cells may contribute to the presence of un-

### Table 1  Methylation status of RASSF1A and expression of RASSF1A in ESCC cell lines

<table>
<thead>
<tr>
<th>RASSF1A methylation status</th>
<th>ESCC</th>
<th>RASSF1A expression (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methylated allele</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Unmethylated allele</td>
<td>+</td>
<td>14</td>
</tr>
<tr>
<td>+</td>
<td>+</td>
<td>3</td>
</tr>
<tr>
<td>-</td>
<td>+</td>
<td>6</td>
</tr>
</tbody>
</table>

*a ESCC, esophageal squamous cell carcinoma.

$b p = 0.007$; Fisher’s exact test.

Fig. 1  Representative MSP (A) and RT-PCR (B) analysis in esophageal squamous cell carcinoma cell lines (TE1, 3, and 4). A, MSP of the RASSF1A promoter by using both unmethylated (U) and methylated (M)-specific primers. In vitro methylated DNA was used as a positive control (PC) for amplification with methylated-specific primers. NC, negative control. B, RT-PCR analysis of RASSF1A. Arrows, location of transcripts. GAPDH amplification served as a control for cDNA quality.
methylated bands in many cases. Unmethylated bands were detected in all of the 48 corresponding noncancerous tissues. Two of 48 noncancerous tissues (4%) showed methylated bands. Representative MSP results of esophageal squamous cell carcinomas are shown in Fig. 2A. The PCR products obtained with unmethylated and methylated primers of three different tumors and corresponding noncancerous tissues were directly sequenced. In the PCR product from unmethylated primers, all unmethylated cytosine nucleotides, including those in the CpG dinucleotides, changed to thymines as a result of bisulfite modification. Cytosine nucleotides in the CpG dinucleotides were found to remain as cytosine, which indicated the presence of methylated DNA (Fig. 2B).

The results of statistical analysis for correlation of RASSF1A promoter methylation status in the tumor tissues with histological differentiation and tumor stage are shown in Table 2. There were no significant correlations of RASSF1A promoter hypermethylation with age and histological differentiation. However, there was a significant correlation between RASSF1A promoter hypermethylation and tumor stage ($P = 0.009$; Fisher’s exact test).

RASSF1A expression was examined by RT-PCR in 23 primary esophageal squamous cell carcinomas and corresponding noncancerous tissues. RT-PCR analysis demonstrated that no RASSF1A transcripts were amplified from 9 tumor tissues. In all of the 9 tumors with the RASSF1A promoter hypermethylation, RASSF1A was not expressed. The remaining 14 tumors and all 23 noncancerous tissues showed RASSF1A expression. In 9 of 14 tumors, RASSF1A was expressed with the nonhypermethylation of the RASSF1A promoter (Table 3). Overall, there was a significant correlation between RASSF1A promoter hypermethylation and loss of RASSF1A expression in clinical samples ($P = 0.003$; Fisher’s exact test). Representative RT-PCR results of esophageal squamous cell carcinomas are shown in Fig. 2C.

**DISCUSSION**

Several studies have suggested that chromosome 3p21 contains a candidate tumor suppressor gene involved in various tumor types (4, 5, 8, 9). The RASSF1A gene is a novel candidate tumor suppressor gene that was isolated from this region (10). The RASSF1A protein shows high homology to the mouse Ras effector protein Nore1 (10). Nore1 directly interacts with Ras in a GTP-dependent manner and follows receptor activation (18). Promoter hypermethylation has been reported to be the major mechanism of RASSF1A inactiva-

---

**Table 2** Clinicopathological correlation of RASSF1A promoter hypermethylation

<table>
<thead>
<tr>
<th>RASSF1A methylation status</th>
<th>Hypermethylation</th>
<th>Nonhypermethylation</th>
<th>$P^a$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (mean ± SD; yr)</td>
<td>60.4 ± 7.4</td>
<td>61.0 ± 7.6</td>
<td></td>
</tr>
<tr>
<td>Differentiation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Well</td>
<td>4</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>Moderate</td>
<td>15</td>
<td>11</td>
<td>0.544</td>
</tr>
<tr>
<td>Low</td>
<td>6</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I/II</td>
<td>1</td>
<td>8</td>
<td>0.009</td>
</tr>
<tr>
<td>III/IV</td>
<td>24</td>
<td>15</td>
<td></td>
</tr>
</tbody>
</table>

$^a$ Fisher’s exact test.

**Table 3** Methylation status of RASSF1A and expression of RASSF1A in primary esophageal squamous cell carcinomas

<table>
<thead>
<tr>
<th>RASSF1A expression</th>
<th>RASSF1A methylation status</th>
</tr>
</thead>
<tbody>
<tr>
<td>+</td>
<td>Hypermethylation</td>
</tr>
<tr>
<td>-</td>
<td>Nonhypermethylation</td>
</tr>
</tbody>
</table>

| $P = 0.003$; Fisher’s exact test. |

---

**Fig. 2** Representative MSP (A), direct sequence of PCR products (B), and RT-PCR (C) analysis in primary esophageal squamous cell carcinomas. A, MSP analysis from two cases, cases 3 and 8. MSP of the RASSF1A promoter by using both unmethylated (U) and methylated (M)-specific primers. PC, positive control; NC, negative control; T, tumor; N, corresponding normal tissue. B, direct sequencing chromatogram of PCR products from case 8. The CpG sites are marked by a bar and methylated cytosine by an asterisk. C, RT-PCR analysis of RASSF1A from two cases, cases 3 and 8. Arrow, location of transcript. GAPDH amplification served as a control for cDNA quality.
tion in several cancers (14–16). In the present study, we found hypermethylation of RASSF1A in 52% of primary esophageal squamous cell carcinoma. In addition, there was a significant concordance between RASSF1A promoter methylation status and its expression. These findings indicate that hypermethylation of RASSF1A promoter may represent a common mechanism of inactivation of this candidate tumor suppressor gene in primary esophageal squamous cell carcinomas.

Recently, Maruyama et al. (19) reported that promoter hypermethylation of RASSF1A was significantly correlated with several parameters of poor prognosis of bladder cancers. Here, we demonstrated that RASSF1A hypermethylation is correlated with tumor stage in patients with esophageal squamous cell carcinoma. These findings suggest that in many cases, RASSF1A hypermethylation may occur as a late event during the progression of esophageal squamous cell carcinomas. Thus, RASSF1A hypermethylation may be a potential new prognostic marker of esophageal squamous cell carcinomas.

In this study, RASSF1A promoter hypermethylation of noncancerous tissues was detected in 4% (2 of 48) of patients with esophageal squamous cell carcinoma. This finding suggests that RASSF1A promoter hypermethylation could be an early event in the pathogenesis of only few cases of esophageal squamous cell carcinomas. Furthermore, the presence of the hypermethylation in corresponding noncancerous tissues may represent the appearance of premalignant lesions. We also found that 5 of 14 cases showing hypermethylation showed RASSF1A expression. This finding can be explained by the partial methylation of RASSF1A promoter. Several studies have reported that partial methylation could cause gene expression in the tumor cells despite promoter hypermethylation (20, 21). Another possibility for explaining this result is the high sensitivity of the MSP analysis. In fact, MSP can detect about one methylated gene copy in 1000 unmethylated copies in dilution experiments (22). MSP analysis is a sensitive, simple, and useful method, and MSP analysis of RASSF1A may thus contribute to an improved outcome of patients with esophageal squamous cell carcinoma.

In summary, hypermethylation of RASSF1A promoter region is observed frequently in esophageal squamous cell carcinomas and associated with loss of mRNA expression in many cases. Our results suggest that hypermethylation of RASSF1A may play an important role in RASSF1A inactivation in esophageal squamous cell carcinogenesis. The further study of RASSF1A involvement in esophageal squamous cell carcinoma and delineation of metabolic pathways in which this gene is involved may lead to therapeutic alternatives for this cancer.

REFERENCES


Promoter Hypermethylation of RASSF1A in Esophageal Squamous Cell Carcinoma

Tamotsu Kuroki, Francesco Trapasso, Sai Yendamuri, et al.